Department of Pediatrics, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA.
Circulation. 2010 Nov 23;122(21):2123-30. doi: 10.1161/CIRCULATIONAHA.110.948737. Epub 2010 Nov 8.
Children undergoing congenital heart surgery often receive corticosteroids with the aim of reducing the inflammatory response after cardiopulmonary bypass; however, the value of this approach is unclear.
The Pediatric Health Information Systems Database was used to evaluate outcomes associated with corticosteroids in children (0 to 18 years of age) undergoing congenital heart surgery at 38 US centers from 2003 to 2008. Propensity scores were constructed to account for potential confounders: age, sex, race, prematurity, genetic syndrome, type of surgery (Risk Adjustment in Congenital Heart Surgery [RACHS-1] category), center, and center volume. Multivariable analysis, adjusting for propensity score and individual covariates, was performed to evaluate in-hospital mortality, postoperative length of stay, duration of ventilation, infection, and use of insulin. A total of 46 730 children were included; 54% received corticosteroids. In multivariable analysis, there was no difference in mortality among corticosteroid recipients and nonrecipients (odds ratio, 1.13; 95% confidence interval, 0.98 to 1.30). Corticosteroids were associated with longer length of stay (least square mean difference, 2.18 days; 95% confidence interval, 1.62 to 2.74 days), greater infection (odds ratio, 1.27; 95% confidence interval, 1.10 to 1.46), and greater use of insulin (odds ratio, 2.45; 95% confidence interval, 2.24 to 2.67). There was no difference in duration of ventilation. In analysis stratified by RACHS-1 category, no significant benefit was seen in any group, and the association of corticosteroids with increased morbidity was most prominent in RACHS-1 categories 1 through 3.
In this observational analysis of children undergoing congenital heart surgery, we were unable to demonstrate a significant benefit associated with corticosteroids and found that corticosteroids may be associated with increased morbidity, particularly in lower-risk patients.
儿童在接受先天性心脏手术后经常接受皮质类固醇治疗,目的是减轻体外循环后的炎症反应;然而,这种方法的价值尚不清楚。
使用儿科健康信息系统数据库评估了 2003 年至 2008 年期间美国 38 个中心的 46730 名 0 至 18 岁接受先天性心脏手术的儿童使用皮质类固醇的结局。构建倾向评分以考虑潜在的混杂因素:年龄、性别、种族、早产、遗传综合征、手术类型(先天性心脏手术风险调整 [RACHS-1] 类别)、中心和中心容量。进行多变量分析,调整倾向评分和个体协变量,以评估院内死亡率、术后住院时间、通气时间、感染和胰岛素使用情况。共有 46730 名儿童被纳入;54%的儿童接受了皮质类固醇治疗。多变量分析显示,皮质类固醇治疗组与非治疗组的死亡率无差异(比值比,1.13;95%置信区间,0.98 至 1.30)。皮质类固醇与住院时间延长有关(最小二乘均数差异,2.18 天;95%置信区间,1.62 至 2.74 天)、感染增加(比值比,1.27;95%置信区间,1.10 至 1.46)和胰岛素使用增加(比值比,2.45;95%置信区间,2.24 至 2.67)。通气时间无差异。在 RACHS-1 类别分层分析中,任何组均未显示显著益处,皮质类固醇与发病率增加的关联在 RACHS-1 类别 1 至 3 中最为明显。
在这项对接受先天性心脏手术的儿童进行的观察性分析中,我们未能证明皮质类固醇治疗有显著益处,并发现皮质类固醇可能与发病率增加有关,特别是在低风险患者中。